Market cap
$298,256 Mln
Revenue (TTM)
$65,593 Mln
P/E Ratio
34
P/B Ratio
6.4
Div. Yield
2.8 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$13,175 Mln
-
ROE
0.2 %
-
ROCE
19.4 %
-
Industry P/E
30.86
-
EV/EBITDA
17.4
-
Debt to Equity
1
-
Book Value
$18.6
-
EPS
$3.6
-
Face value
--
-
Shares outstanding
2,469,824,415
10 Years Aggregate
CFO
$117,929.00 Mln
EBITDA
$115,983.00 Mln
Net Profit
$75,684.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
| 14.0 | 7.8 | 3.3 | 49.4 | 2.7 | 9.5 | 8.3 |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
| 5.8 | -8.7 | -1.7 | 44.8 | 1.9 | -7.1 | 22.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Merck & Company Inc (MRK)
|
120.0 | 298,256.0 | 65,593.0 | 8,935.0 | 24.7 | 18.3 | 34 | 6.4 |
| 354.9 | 188,671.2 | 37,238.0 | 7,800.0 | 29.1 | 82.9 | 24.3 | 20.5 | |
| 200.9 | 28,839.4 | 9,857.4 | 1,372.4 | 19.3 | 7.4 | 21 | 1.5 | |
| 57.1 | 116,663.5 | 48,482.0 | 7,275.0 | 21.6 | 37.7 | 16 | 5.8 | |
| 224.1 | 52,427.0 | 250,549.0 | 1,559.0 | 0.9 | -- | 34.1 | 16.1 | |
| 125.5 | 160,361.2 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 17.6 | 6.8 | |
| 789.5 | 94,623.4 | 403,430.0 | 4,762.0 | 1.6 | -246.4 | 20.5 | 5.0 | |
| 153.5 | 293,693.5 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 22.1 | 7.6 | |
| 26.2 | 149,154.5 | 63,315.0 | 7,491.0 | 16.7 | 8.1 | 20 | 1.6 | |
| 80.3 | 33,358.0 | 9,509.0 | 2,643.0 | 37.3 | 61.2 | 13 | 10.3 |
Shareholding Pattern
View DetailsAbout Merck & Company Inc (MRK)
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23,... Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey. Read more
-
Chairman, President & CEO
Mr. Robert M. Davis J.D.
-
Chairman, President & CEO
Mr. Robert M. Davis J.D.
-
Headquarters
Rahway, NJ
-
Website
FAQs for Merck & Company Inc (MRK)
What is the current share price of Merck & Company Inc (MRK) Today?
The share price of Merck & Company Inc (MRK) is $120.00 (NYSE) as of 12-Jun-2026 13:48 EDT. Merck & Company Inc (MRK) has given a return of 2.72% in the last 3 years.
What is the current PB & PE ratio of Merck & Company Inc (MRK)?
The P/E ratio of Merck & Company Inc (MRK) is 34.02 times as on 12-Jun-2026, a 10 premium to its peers’ median range of 30.86 times.
The P/B ratio of Merck & Company Inc (MRK) is 6.41 times as on 12-Jun-2026, a 11 premium to its peers’ median range of 5.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
14.35
|
4.98
|
|
2024
|
14.77
|
5.46
|
|
2023
|
762.89
|
7.41
|
|
2022
|
19.47
|
6.15
|
|
2021
|
14.89
|
5.09
|
What is the 52 Week High and Low of Merck & Company Inc (MRK)?
The 52-week high and low of Merck & Company Inc (MRK) are Rs 125.14 and Rs 76.66 as of 14-Jun-2026.
What is the market cap of Merck & Company Inc (MRK)?
Merck & Company Inc (MRK) has a market capitalisation of $ 298,256 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Merck & Company Inc (MRK)?
Before investing in Merck & Company Inc (MRK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.